attachment
attachment

Give crisp and concise answer from latest edition of Harrison's medicine

analyse_media
analyse_media
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here are complete, crisp answers from Harrison's Principles of Internal Medicine 22nd Edition (2025):

SECTION A - MCQs (Answers with Rationale)

QAnswerKey Rationale (Harrison's)
1(c) Mycoplasma pneumoniaeMost common cause of atypical (walking) pneumonia; extrapulmonary features include cold agglutinin-mediated hemolytic anemia, Stevens-Johnson syndrome, and neurologic manifestations
2(a) Decreased FEV1/FVC ratio with bronchodilator reversibilityAsthma = obstructive pattern; FEV1/FVC <0.70, with ≥12% reversibility after bronchodilator
3(d) Lichen PlanusClassic "5 P's": Purple, Polygonal, Planar, Pruritic, Papules on flexor wrists; Wickham's striae seen
4(b) Erythema Chronicum MigransPathognomonic of Lyme disease (Borrelia burgdorferi); expanding bull's-eye rash at tick bite site
5(d) Pityriasis RoseaHerald patch precedes "Christmas tree" distribution of lesions along Langer's lines on the trunk
6(c) Auditory HallucinationsPositive symptoms = added phenomena (hallucinations, delusions, disorganized speech). Social withdrawal, anhedonia, alogia = negative symptoms
7(b) LithiumDrug of choice for acute mania and long-term maintenance; also has anti-suicidal properties
8(a) IgEType I hypersensitivity (anaphylactic/allergic) is mediated by IgE bound to mast cells and basophils
9(b) Inhibition of acetylcholinesteraseOrganophosphates irreversibly inhibit AChE → ACh accumulation → muscarinic effects including miosis
10(d) NaloxoneCompetitive opioid receptor antagonist; dose 0.4-2 mg IV; reverses respiratory depression, miosis, and coma
11(b) Bamboo SpineAnkylosing Spondylitis: ossification of annulus fibrosus + anterior longitudinal ligament → "bamboo spine" on X-ray
12(a) Reactive ArthritisReiter's syndrome (urethritis + conjunctivitis + arthritis) = Reactive Arthritis; triggered by Chlamydia, Salmonella, Shigella, Campylobacter
13(c) Trisomy 21Down Syndrome = three copies of chromosome 21; most commonly due to meiotic non-disjunction
14(d) Marfan SyndromeAutosomal dominant (fibrillin-1 gene, chromosome 15); Thalassemia = AR; PKU = AR; Cystic Fibrosis = AR
15(b) Enteric Fever (Typhoid)Widal test detects agglutinating antibodies against O and H antigens of Salmonella typhi
16(c) ArsenicChronic arsenic poisoning: Mees' lines on nails, raindrop pigmentation (alternating hyperpigmentation/depigmentation), arsenical keratosis
17(a) Aedes aegyptiPrimary vector of Dengue, Zika, Chikungunya, Yellow Fever; breeds in stagnant clean water
18(b) PrimaquineRadical cure of P. vivax/P. ovale (kills liver hypnozoites); must test for G6PD deficiency first
19(b) Rifampicin, Dapsone, and ClofaziminePaucibacillary: Rifampicin + Dapsone × 6 months. Multibacillary: Rifampicin + Dapsone + Clofazimine × 12 months
20(a) Respiratory FailureElapid (cobra, krait) venom → neurotoxic → neuromuscular blockade → respiratory muscle paralysis → death

SECTION B

Q1 - Lobar Pneumonia (35-year-old with rusty sputum, bronchial breathing)

(a) Diagnosis

Community-Acquired Pneumonia (Pneumococcal/Lobar Pneumonia) caused by Streptococcus pneumoniae. Rusty sputum, bronchial breathing, and increased vocal fremitus in a lobar distribution are classic.

(b) Pathogenesis and Pathological Stages

Pathogenesis: S. pneumoniae colonizes nasopharynx → aspirated into lungs → evades mucociliary clearance → polysaccharide capsule inhibits phagocytosis → alveolar inflammation.
4 Classic Stages (Laennec):
  1. Congestion (24h): Vascular engorgement, serous exudate; lung heavy and red
  2. Red Hepatization (2-3 days): Alveoli filled with RBCs, fibrin, neutrophils; lung firm, red, liver-like
  3. Grey Hepatization (4-8 days): RBC lysis; neutrophils and fibrin persist; lung grey
  4. Resolution (8+ days): Macrophages clear debris; normal architecture restored

(c) Investigations and CURB-65 Score

Investigations:
  • CXR: lobar/segmental consolidation
  • Sputum Gram stain and culture
  • CBC: leukocytosis (WBC >12,000)
  • Blood cultures (2 sets)
  • ABG if SpO2 <94%
  • Urine pneumococcal antigen
  • Serum electrolytes, BUN, creatinine
CURB-65 Score (1 point each): | C | Confusion (new onset) | | U | Urea >7 mmol/L (BUN >19 mg/dL) | | R | Respiratory rate ≥30/min | | B | Blood pressure: systolic <90 or diastolic ≤60 mmHg | | 65 | Age ≥65 years |
  • Score 0-1: Outpatient
  • Score 2: Consider hospitalization
  • Score 3-5: Hospitalize; ICU if score 4-5

(d) Management for Hospitalized Patient

  • Beta-lactam (IV amoxicillin-clavulanate or ceftriaxone 1g IV OD) PLUS macrolide (azithromycin 500 mg OD) - Harrison's preferred empiric regimen
  • OR Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg IV/OD)
  • ICU patients: beta-lactam + azithromycin or anti-pneumococcal fluoroquinolone
  • Supplemental O2 to maintain SpO2 >94%
  • IV fluids if hypotensive
  • Antipyretics
  • Thromboprophylaxis (low-molecular-weight heparin)
  • Duration: 5 days (if clinically stable); de-escalate to oral when afebrile ×48h

Q2a - Falciparum Malaria: Clinical Features and Complications

Clinical Features:
  • Fever (may be irregular, not classic tertian)
  • Headache, myalgia, nausea, vomiting
  • Splenomegaly, hepatomegaly
  • Anemia, thrombocytopenia
Severe/Complications (WHO criteria):
ComplicationMechanism
Cerebral malariaSequestration of parasitized RBCs in brain microvasculature → coma, seizures
Blackwater feverMassive intravascular hemolysis → hemoglobinuria, renal failure
Acute Renal FailureHemoglobinuria + cytokine damage
ARDS/Pulmonary edemaCapillary leak
HypoglycemiaGlucose consumption by parasites + quinine-induced hyperinsulinism
Algid malariaCirculatory collapse, cold skin
DICCoagulation cascade activation
Hyperparasitemia>5% parasitized RBCs = severe malaria marker
Treatment of severe falciparum: IV Artesunate (2.4 mg/kg at 0, 12, 24h, then daily) - drug of choice.

Q2b - Leprosy: Diagnosis and WHO Classification

Diagnosis:
  • Clinical: hypopigmented/erythematous skin patches with loss of sensation + thickened peripheral nerves
  • Slit-skin smear: acid-fast bacilli (AFB) from ear lobe/lesion - assessed as Bacterial Index (BI)
  • Skin biopsy: gold standard - granulomas with AFB
  • Lepromin test: measures CMI (positive in tuberculoid, negative in lepromatous)
  • PCR for M. leprae DNA
WHO Field Classification (for MDT purposes):
TypeSkin LesionsNerveSmearTreatment
Paucibacillary (PB)1-5 lesions≤1 nerveNegativeRifampicin + Dapsone × 6 months
Multibacillary (MB)>5 lesions>1 nervePositiveRifampicin + Dapsone + Clofazimine × 12 months
Ridley-Jopling Classification: TT → BT → BB → BL → LL (tuberculoid to lepromatous spectrum)

Q2c - Management of Acute Methanol Poisoning

Mechanism: Methanol → (alcohol dehydrogenase) → Formaldehyde → Formic acid → severe metabolic acidosis + optic nerve toxicity (blindness)
Clinical features: Nausea, vomiting, headache, visual disturbance ("snowstorm vision"), high anion gap metabolic acidosis, elevated osmol gap
Management:
  1. ABC - airway, breathing, circulation
  2. Fomepizole (4-methylpyrazole) 15 mg/kg IV loading - ADH inhibitor, drug of choice (or ethanol 10% IV if fomepizole unavailable)
  3. Sodium bicarbonate - correct metabolic acidosis (pH <7.3)
  4. Folinic acid (Leucovorin) 50 mg IV q4-6h - enhances formate metabolism
  5. Hemodialysis - indicated if: pH <7.25, severe visual impairment, methanol level >25 mg/dL, renal failure
  6. Supportive care; monitor visual acuity

Q2d - HIV/AIDS: Clinical Features and WHO Clinical Staging

Clinical Features by Stage:
WHO Stage 1 (Asymptomatic):
  • Asymptomatic
  • Persistent generalized lymphadenopathy (PGL)
  • CD4 usually >500
WHO Stage 2 (Mild):
  • Weight loss <10%, minor mucocutaneous manifestations
  • Recurrent oral ulcers, seborrheic dermatitis, herpes zoster, recurrent URTIs
WHO Stage 3 (Advanced):
  • Weight loss >10%, chronic diarrhea >1 month
  • Oral candidiasis, oral hairy leukoplakia
  • Pulmonary TB, severe bacterial pneumonia
  • CD4 typically <350
WHO Stage 4 (Severe/AIDS-defining):
  • PCP pneumonia (Pneumocystis jirovecii)
  • Cerebral toxoplasmosis, CNS cryptococcosis
  • CMV retinitis
  • Kaposi's sarcoma, lymphoma
  • HIV wasting syndrome
  • CD4 <200 defines AIDS
Antiretroviral Therapy: Start in ALL patients regardless of CD4 count. Preferred first-line: TDF + 3TC + DTG (Tenofovir + Lamivudine + Dolutegravir)

SECTION B - Q3

(a) Primary Chancre in Syphilis

  • Single (occasionally multiple), painless, clean-based ulcer
  • Well-demarcated, indurated (hard) edges - "cartilaginous feel"
  • Appears 10-90 days (mean 3 weeks) after inoculation with Treponema pallidum
  • Size: 0.5-2 cm
  • Located at site of inoculation (glans, prepuce, vulva, cervix, anus)
  • Associated with painless, non-tender regional lymphadenopathy (inguinal)
  • Heals spontaneously in 3-6 weeks without treatment
  • Highly infectious - dark-field microscopy shows spirochetes

(b) Vitamin A Deficiency - Ocular Manifestations

In order of progression (WHO grading):
  1. Night blindness (Nyctalopia) - earliest; rhodopsin synthesis impaired
  2. Conjunctival xerosis (X1A) - dry, non-wettable conjunctiva
  3. Bitot's spots (X1B) - foamy, cheese-like plaques on temporal conjunctiva (triangular, can't be wiped off)
  4. Corneal xerosis (X2) - dry, hazy cornea
  5. Corneal ulceration/keratomalacia (X3A/X3B) - colliquative necrosis; irreversible blindness
  6. Corneal scar (XS) - leucoma
Treatment: Vitamin A capsule 200,000 IU orally on days 1, 2, and 14.

(c) Koebner Phenomenon

Definition: Appearance of skin lesions characteristic of a disease at sites of trauma or injury to previously normal skin.
3 Classic Examples:
  1. Psoriasis - most classic; new plaques form at scratch/trauma sites
  2. Lichen Planus - purple papules appear along scratch lines
  3. Vitiligo - depigmented patches at sites of injury
Other examples: warts (viral koebnerization), molluscum contagiosum

(d) Bipolar I vs. Bipolar II Disorder

FeatureBipolar IBipolar II
Manic episodesFull mania (≥7 days, hospitalization may be needed)Absent
Hypomanic episodesMay occurPresent (≥4 days, not requiring hospitalization)
Depressive episodesUsually presentProminent/required for diagnosis
PsychosisCan occur during maniaDoes not occur in hypomania
SeverityMore severeLess severe overall, but depression can be disabling
HospitalizationMay be required for maniaNot required for hypomania
Key pointMania alone = Bipolar INo full mania ever = Bipolar II

(e) Post-Exposure Prophylaxis (PEP) for Rabies

Wound Management (immediate, most important):
  • Wash wound with soap and water for ≥15 min
  • Apply povidone-iodine or 70% alcohol
Rabies Immunoglobulin (RIG): 20 IU/kg (human RIG) or 40 IU/kg (equine RIG)
  • Inject as much as possible into and around the wound
  • Remainder given IM at distant site
  • Given only on Day 0 (only if not previously vaccinated)
Rabies Vaccine (Essen regimen - WHO recommended):
  • Days 0, 3, 7, 14 (4-dose IM schedule) - for previously unvaccinated
  • Previously vaccinated: Days 0 and 3 only (no RIG needed)
Category of exposure:
  • Cat I (touching, feeding, licking intact skin): No PEP
  • Cat II (nibbling, minor scratches): Vaccine only
  • Cat III (transdermal bite, bat exposure, mucosal lick): Vaccine + RIG

SECTION C

Q1 - Ankylosing Spondylitis

(a) Diagnosis

Ankylosing Spondylitis (AS) - a seronegative spondyloarthropathy. Classic presentation: young male <45 years, insidious-onset low back pain >3 months, morning stiffness improving with exercise (not rest), anterior uveitis, reduced spinal flexion.

(b) Significance of HLA-B27

  • HLA-B27 is a class I MHC molecule; present in 90-95% of AS patients (vs. 8% in general population)
  • Relative risk of AS with HLA-B27 positivity: ~100x
  • Mechanism: molecular mimicry between HLA-B27 and bacterial antigens (Klebsiella), misfolded protein theory, free heavy chain theory
  • Not diagnostic alone - 8% of HLA-B27 positive individuals develop AS
  • Also associated with other spondyloarthropathies: Reactive arthritis, psoriatic arthritis, IBD-associated arthritis
  • Useful for supporting diagnosis when clinical features and X-ray are equivocal
  • HLA-B27 positive children with arthritis + uveitis = high-risk group

(c) Schober's Test

Purpose: Objectively measures lumbar spinal flexion (detects reduced mobility in AS)
Technique:
  1. Patient stands erect; mark a point at L5 (lumbosacral junction)
  2. Mark a second point 10 cm above and another 5 cm below this mark (15 cm total span)
  3. Patient asked to bend forward maximally
  4. Remeasure the distance between the two outer marks
Interpretation:
  • Normal: distance increases by ≥5 cm (from 15 cm to ≥20 cm)
  • Abnormal (<5 cm increase): suggests reduced lumbar flexion as seen in AS

(d) Management including TNF Inhibitors

Non-pharmacological:
  • Exercise, physiotherapy, hydrotherapy
  • Posture training to prevent kyphosis
  • Smoking cessation
Pharmacological:
NSAIDs (first-line):
  • Indomethacin, diclofenac, naproxen - continuous use preferred over PRN
  • If first NSAID fails, try second NSAID before escalating
Second-line - Biologics (TNF inhibitors):
  • Indicated when: inadequate response to 2 NSAIDs over 4 weeks each
  • Agents: Etanercept, Adalimumab, Infliximab, Certolizumab, Golimumab
  • Reduce inflammation, improve function, slow radiographic progression
  • Screen for latent TB before starting (with tuberculin test/IGRA)
IL-17 inhibitors (alternative biologics):
  • Secukinumab, Ixekizumab - particularly effective for skin and joint disease
Surgical: Total hip replacement for advanced hip involvement; spinal osteotomy for severe kyphosis

Q2a - Neurotoxic vs. Vasculotoxic Snake Bite

FeatureNeurotoxic (Elapid)Vasculotoxic (Viper)
SnakesCobra, Krait, MambaRussell's viper, Saw-scaled viper, Pit viper
MechanismPre-synaptic (krait): blocks ACh release; Post-synaptic (cobra): blocks nAChRProteases, hyaluronidase, phospholipases → local tissue destruction, coagulopathy
Local effectsMinimal swellingSevere swelling, necrosis, blister formation
Systemic featuresPtosis (earliest sign), diplopia, dysphagia, respiratory paralysis, areflexiaBleeding (hemotoxin): ecchymosis, hematuria, hematemesis, DIC
PupilsDilated (cobra)Normal
Death causeRespiratory failureHemorrhage, ARF
20WBCT testNormalAbnormal (blood doesn't clot in 20 min)
TreatmentPolyvalent ASV + neostigmine (for post-synaptic) + atropine; ventilatory supportPolyvalent ASV; FFP, platelets; manage ARF with dialysis
Anti-snake venom (ASV):
  • Polyvalent ASV given IV (preferred over IM)
  • Dose: 10 vials initial; repeat if no improvement in 1-2 hours
  • Indications: coagulopathy, neurotoxicity, hemoglobinuria, local necrosis

Q2b - Status Asthmaticus Management (Emergency Department)

Definition: Severe asthma attack not responding to initial bronchodilator therapy.
Initial Assessment: SpO2, PEFR/FEV1, ABG, RR, use of accessory muscles, ability to speak.
Step-by-step ED Management:
  1. Oxygen: 40-60% to maintain SpO2 93-95% (not high-flow routinely)
  2. SABA (first-line): Salbutamol (albuterol) 2.5-5 mg nebulized q20min × 3 doses in first hour, then q1-4h; or MDI 4-8 puffs q20min
  3. Ipratropium bromide: 0.5 mg nebulized q20min × 3 (add to SABA for severe attacks)
  4. Systemic corticosteroids (mandatory): Prednisolone 40-60 mg oral or Hydrocortisone 100-200 mg IV; continue 5-7 days
  5. IV Magnesium sulfate: 2g IV over 20 min - for severe/life-threatening attacks not responding to above (bronchosmolytics via calcium channel mechanism)
  6. IV aminophylline: No longer recommended as first-line; use only if no response to above
  7. Heliox (helium-oxygen mixture): Consider if failing
  8. NIV/BiPAP: In impending respiratory failure
  9. Intubation/Mechanical ventilation: Last resort; aim for permissive hypercapnia, low PEEP
Discharge criteria: PEFR >75% predicted, SpO2 >94% on room air, sustained for 1 hour

Q2c - Scleroderma: Clinical Manifestations and CREST Syndrome

Two Main Forms:
  • Diffuse cutaneous SSc (dcSSc): Rapid skin involvement proximally + internal organs
  • Limited cutaneous SSc (lcSSc): Skin confined to distal extremities/face = CREST syndrome
CREST Syndrome (lcSSc):
LetterFeatureDetail
CCalcinosis cutisCalcium deposits in skin/soft tissues, especially fingers
RRaynaud's phenomenonEpisodic digital vasospasm (white → blue → red with cold/stress)
EEsophageal dysmotilityDysphagia, GERD; lower 2/3 of esophagus affected
SSclerodactylyTight, shiny skin of fingers; "sausage fingers"
TTelangiectasiaDilated capillaries on face, lips, hands
Anti-centromere antibody is the hallmark of lcSSc/CREST (>90% sensitive).
Other systemic features: Pulmonary arterial hypertension (leading cause of death in lcSSc), interstitial lung disease, renal crisis (in dcSSc), Sjogren's overlap.

Q2d - Genetic Counseling: Ethical Considerations and Steps

Steps:
  1. Referral and indication - family history, advanced maternal age, abnormal prenatal screening
  2. Information gathering - 3-generation pedigree, medical records
  3. Risk estimation - calculate recurrence risk using Mendelian principles
  4. Education - explain disease, inheritance pattern, variability, penetrance
  5. Discussion of options - prenatal diagnosis (amniocentesis, CVS, FISH/microarray), preimplantation genetic diagnosis, adoption, childlessness
  6. Decision support (non-directive counseling)
  7. Follow-up - psychological support, referral to support groups
Ethical Principles:
  • Autonomy: Non-directive counseling; patient decides freely without coercion
  • Beneficence: Provide accurate information for informed decisions
  • Non-maleficence: Avoid unnecessary anxiety; disclose information responsibly
  • Confidentiality: Genetic information is private; duty to warn at-risk relatives (conflict)
  • Justice: Equal access to genetic services
  • Informed consent: Voluntary, capacity-based, with full disclosure
  • Disclosure to third parties (insurers, employers) is generally prohibited

SECTION C - Q3

(a) Laboratory Diagnosis of Kala-azar (Visceral Leishmaniasis)

  • Definitive: Demonstration of Leishmania donovani (LD bodies/amastigotes)
    • Splenic aspirate - most sensitive (>95%) but risky
    • Bone marrow aspirate - safer, 70-80% sensitive
    • Liver biopsy, lymph node aspirate
  • Serological (used in endemic areas):
    • rK39 immunochromatographic test (ICT) - rapid, highly sensitive and specific; point-of-care test of choice
    • DAT (Direct Agglutination Test)
    • ELISA for anti-leishmanial antibodies
  • Molecular: PCR - highly sensitive, not routine
  • Blood: CBC shows pancytopenia (anemia, leucopenia, thrombocytopenia), elevated ESR, hypergammaglobulinemia, hypoalbuminemia

(b) Anaphylaxis Management - Drug and Dose

Epinephrine (Adrenaline) = cornerstone - give FIRST and immediately
DrugDoseRouteTiming
Epinephrine0.3-0.5 mg (adult); 0.01 mg/kg in children (max 0.5mg) of 1:1000 solutionIM (anterolateral thigh)Immediately
Oxygen100%, 15 L/min via non-rebreather maskInhalationImmediately
IV Fluids1-2 L normal saline bolusIVIf hypotensive
Diphenhydramine (H1 blocker)25-50 mg IV/IMIV/IMAfter epi
Ranitidine/Famotidine (H2 blocker)50 mg IVIVAfter epi
Hydrocortisone200 mg IVIVAfter epi (prevents biphasic)
Salbutamol nebulization2.5-5 mgInhaledIf bronchospasm
Biphasic anaphylaxis (second reaction 8-72h later): observe for minimum 6 hours before discharge.

(c) Obsessive-Compulsive Disorder (OCD) - Clinical Features

Obsessions (intrusive, unwanted, ego-dystonic thoughts/images/urges):
  • Contamination (dirt, germs)
  • Harm (fear of hurting self/others)
  • Symmetry, exactness
  • Religious/sexual thoughts
Compulsions (repetitive behaviors/mental acts to neutralize obsessions):
  • Washing/cleaning (most common)
  • Checking (locks, appliances)
  • Counting, arranging
  • Hoarding
Diagnostic criteria (DSM-5):
  • Obsessions and/or compulsions that are time-consuming (>1h/day) and cause significant distress/impairment
  • Ego-dystonic (recognized as excessive/unreasonable)
  • Not attributable to substances or medical condition
Y-BOCS (Yale-Brown) scale used to assess severity.
Treatment: First-line: SSRIs (fluoxetine, fluvoxamine, sertraline) + CBT with Exposure and Response Prevention (ERP)

(d) Dermatological Features of Scabies and the Burrow

Causative agent: Sarcoptes scabiei var. hominis (mite)
Burrow:
  • Pathognomonic of scabies
  • A tortuous, grayish-white or skin-colored linear track (5-15 mm long)
  • Created by the female mite tunneling into stratum corneum to lay eggs
  • Found characteristically in: finger webs (earliest and most common), flexor wrists, genitalia, buttocks, areola, umbilicus
  • Dermoscopy: shows "delta-wing jet" sign (mite at end of burrow)
Other features:
  • Intense pruritus (worse at night - hallmark)
  • Papules, vesicles, excoriations from scratching
  • Burrows are pathognomonic
  • Secondary bacterial infection (impetigo)
  • Norwegian (crusted) scabies: hyperkeratotic plaques; thousands of mites; in immunocompromised
Treatment: Permethrin 5% cream (drug of choice) - apply to entire body from neck down, wash off after 8-12 hours; repeat after 1 week. Oral ivermectin 200 mcg/kg alternative.

(e) Difference between Delirium and Dementia

FeatureDeliriumDementia
OnsetAcute (hours to days)Insidious (months to years)
CourseFluctuating, worse at nightProgressive, gradually worsening
ConsciousnessImpaired (clouded)Clear until late stages
AttentionMarkedly impairedRelatively preserved early
OrientationDisorientedPreserved early
MemoryShort-term impaired acutelyShort-term first, then long-term
Sleep-wake cycleSeverely disruptedMildly disrupted
HallucinationsCommon (visual > auditory)Less common (visual in LBD)
ReversibilityUsually reversible (treat cause)Irreversible (progressive)
EEGDiffuse slowingNormal early (except prion disease)
DurationDays to weeksYears
Common causesInfection, drugs, metabolic, post-opAlzheimer's, vascular, LBD, FTD
TreatmentTreat underlying cause; haloperidol for agitationCholinesterase inhibitors (donepezil), memantine
Key distinction: Delirium = acute, fluctuating, impaired consciousness; Dementia = chronic, progressive, clear consciousness until late.

All answers based on Harrison's Principles of Internal Medicine, 22nd Edition (2025, McGraw Hill).

Generate a flashcard presentation on Harrison's diagnostic criteria for these conditions

Reading File
Reading File
Running Command
Running Command
Writing File
Running Command
Running Command
Your flashcard presentation is ready!

Harrisons Diagnostic Criteria Flashcards

Presentation · PPTX


What's inside (16 slides total):
SlidesContent
Slide 1Title slide with all 14 condition chips
Slides 2-15One flashcard per condition (see below)
Slide 16Quick reference table - key thresholds + drugs
14 Flashcards covering:
  1. Bronchial Asthma (FEV1/FVC criteria + reversibility)
  2. Community-Acquired Pneumonia (CURB-65 scoring)
  3. Lichen Planus (5 P's + Wickham's striae)
  4. Atypical Pneumonia - Mycoplasma
  5. Ankylosing Spondylitis (modified NY criteria)
  6. Schizophrenia (DSM-5 positive/negative)
  7. OCD (DSM-5 + Y-BOCS)
  8. Bipolar I vs. Bipolar II (side-by-side)
  9. Reactive Arthritis (Reiter's triad)
  10. Scleroderma CREST syndrome
  11. HIV/AIDS WHO Clinical Staging
  12. Kala-azar / Visceral Leishmaniasis
  13. Anaphylaxis (WAO criteria + Epinephrine dose)
  14. Down Syndrome (Trisomy 21)
Each card has: Diagnostic criteria bullets + a mnemonic box + a key fact box, all color-coded by specialty (Respiratory = teal, Psychiatry = red/purple, Rheumatology = gold, Infectious Disease = green/orange).
This is a shared conversation. Sign in to Orris to start your own chat.